- Home
- UPLD vs NRXP Comparison
UPLD vs NRXP Comparison
Compare UPLD & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPLD
- NRXP
- Stock Information
- Founded
- UPLD 2010
- NRXP 2015
- Country
- UPLD United States
- NRXP United States
- Employees
- UPLD N/A
- NRXP N/A
- Industry
- UPLD Computer Software: Prepackaged Software
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- UPLD Technology
- NRXP Health Care
- Exchange
- UPLD Nasdaq
- NRXP Nasdaq
- Market Cap
- UPLD 51.0M
- NRXP 58.5M
- IPO Year
- UPLD 2014
- NRXP N/A
- Fundamental
- Price
- UPLD $1.85
- NRXP $2.48
- Analyst Decision
- UPLD Hold
- NRXP Strong Buy
- Analyst Count
- UPLD 1
- NRXP 4
- Target Price
- UPLD N/A
- NRXP $28.50
- AVG Volume (30 Days)
- UPLD 249.8K
- NRXP 142.0K
- Earning Date
- UPLD 07-31-2025
- NRXP 08-18-2025
- Dividend Yield
- UPLD N/A
- NRXP N/A
- EPS Growth
- UPLD N/A
- NRXP N/A
- EPS
- UPLD N/A
- NRXP N/A
- Revenue
- UPLD $251,757,000.00
- NRXP N/A
- Revenue This Year
- UPLD N/A
- NRXP N/A
- Revenue Next Year
- UPLD N/A
- NRXP $230.95
- P/E Ratio
- UPLD N/A
- NRXP N/A
- Revenue Growth
- UPLD N/A
- NRXP N/A
- 52 Week Low
- UPLD $1.69
- NRXP $1.10
- 52 Week High
- UPLD $5.64
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- UPLD 43.48
- NRXP 29.01
- Support Level
- UPLD $1.98
- NRXP $2.42
- Resistance Level
- UPLD $2.52
- NRXP $2.79
- Average True Range (ATR)
- UPLD 0.26
- NRXP 0.13
- MACD
- UPLD -0.03
- NRXP -0.05
- Stochastic Oscillator
- UPLD 2.80
- NRXP 5.48
About UPLD Upland Software Inc.
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.